Yearly Archives: "2016"

CMSC 2016 Annual Meeting – physical training with assistive devices improves mobility for multiple sclerosis patients
The use of assistive devices is ineffective for multiple sclerosis (MS) patients, a study recently presented at the Consortium of Multiple [...]
CMSC 2016 Annual Meeting – Fingolimod (Gilenya) offers consistent health benefits in RRMS patients
Researchers at the Swedish Neuroscience Institute in Washington and Novartis Pharma revealed that Gilenya (fingolimod) induced a [...]
‘Multiple sclerosis does not remit’ – call to change RRMS name to relapsing multiple sclerosis
MS does not remit and the out dated term causes many people to delay taking medication, says Dr Patricia Coyle, Founder and Director of [...]
CMSC 2016 Annual Meeting – multiple sclerosis mice show reduced disease severity after treatment with vegetable compound
Research from Indiana University School of Medicine showed that D3T – a compound that triggers copying of antioxidant genes and [...]
CMSC 2016 Annual Meeting – multiple sclerosis patients, physical therapists have distinct decision-making processes
Understanding and combining decision-making processes of both patients with multiple sclerosis (MS) and physical therapists to improve [...]
CMSC 2016 Annual Meeting – home DVD-guided exercise may help older multiple sclerosis patients
Positive results from a home-based exercise intervention designed to target flexibility, toning, and balance for older adults with multiple [...]
CMSC 2016 Annual Meeting – multiple sclerosis duration and disability level variously impacts arm function
Most research in multiple sclerosis (MS) has focused on the impact of the disease on the lower extremities. To balance this, researchers [...]
CMSC 2016 Annual Meeting – multiple sclerosis and yoga: author and instructor says ancient discipline can help patients
Mindy Eisenberg is the author of the book “Adaptive Yoga Moves Any Body” and Multiple Sclerosis News Today had the chance to hear [...]
CMSC 2016 Annual Meeting – Ocrevus (Ocrelizumab) in PPMS prevented disability progression
Data recently presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting showed that Roche/Genentech’s [...]
CMSC 2016 Annual Meeting – Genentech’s Ocrelizumab a promising therapy for primary progressive multiple sclerosis
Genentech, a member of the Roche Group, was founded more than 35 years ago and has been focused on a variety of research fields, including [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM